MEXIDOL® 50 mg / ml, 2ml 10s solution intravenously. and intramuscularly. introduction in vials
- $24.90
The instruction for medical use
of MEKSIDOL® medicine
the Trade name
of Meksidol®
the International unlicensed name
Is not present
the Dosage form
Solution for intravenous and intramuscular administration of 50 mg/ml on 2 ml or 5 ml
Structure
of 1 ml of solution contains
active agent - ethylmethylhydroxypyridine succinate - 50 mg,
excipients: sodium metabisulphite, water for injections
the Description
Transparent colourless or slightly yellowish liquid
Pharmacotherapeutic group
Drugs for treatment of diseases of nervous system others.
The ATX N07XX code
the Pharmacological
Pharmacokinetics At properties intramuscular introduction drug is defined in blood plasma for 4 hours after introduction. Time of achievement of the maximum concentration is 0.45 - 0.50 hours. The maximum concentration at doses of 400 - 500 mg makes 3.5 - 4.0 mkg/ml. Мексидол® quickly passes from the blood course into bodies and fabrics and it eliminirutsya quickly from an organism. Time of deduction (MRT) of drug in an organism is 0.7 - 1.3 hours. Drug is removed from an organism with urine generally in a glyukuronokonjyugirovanny form and in insignificant quantities in an invariable look.
The pharmacodynamics
Renders anti-hypoxemic, membranoprotektorny, nootropic, anticonvulsant, anxiolytic action, increases resistance of an organism to a stress. Мексидол® increases resistance of an organism to influence of the major disturbing factors, to kislorodzavisimy morbid conditions (shock, a hypoxia and ischemia, disturbance of cerebral circulation, intoxication alcohol and antipsychotic drugs (neuroleptics)).
Мексидол® improves brain metabolism and blood supply of a brain, improves microcirculation and rheological properties of blood, reduces aggregation of thrombocytes. Stabilizes membrane structures of blood cells (erythrocytes and thrombocytes) at hemolysis. Has hypolipidemic effect, reduces the level of the general cholesterol and lipoproteids of the low density (LDL).
Reduces an enzymatic toxaemia and endogenous intoxication in acute pancreatitis.
The mechanism of action Meksidola® is caused by its antigipoksantny, antioxidant and membranoprotektorny action. It inhibits processes of peroxide oxidation of lipids, increases activity of a superoxide scavenger, the lipid protein raises a ratio, reduces viscosity of a membrane, increases its fluidity. Modulates activity of membrane-bound enzymes (kaltsiynezavisimy phosphodiesterase, adenylatecyclase, acetylcholinesterase), receptor complexes (benzodiazepine, piperidic acid (GAMK), atsetilkholinovy) that enhances their ability of linking with ligands, helps preservation of the structurally functional organization of biomembranes, transport of neurotransmitters and improvement of synoptic transfer. Мексидол® increases dopamine content in a brain. Causes strengthening of compensatory activity of aerobic glycolysis and decrease in extent of oppression of oxidizing processes in a tricarbonic acid cycle in the conditions of a hypoxia, with increase in content of adenosine triphosphate (ATP), creatine phosphate and activation of the power synthesizing functions of mitochondrions, stabilization of cellular membranes.
Мексидол® normalizes metabolic processes in an ischemic myocardium, reduces a necrosis zone, restores and improves electric activity and contractility of a myocardium and also increases a coronary blood stream in an ischemia zone, reduces consequences of a reperfusion syndrome at acute coronary insufficiency. Increases anti-anginal activity of nitrodrugs. Мексидол® promotes preservation of ganglionic cells of a retina and fibers of an optic nerve at the progressing neuropathy which reasons chronic ischemia and a hypoxia are. Improves functional activity of a retina and optic nerve, increasing visual acuity.
Indications
- acute disorders of cerebral circulation
- a craniocereberal injury, consequences of craniocereberal injuries
- distsirkulyatorny encephalopathy
- vegeto-vascular dystonia
- slight cognitive disorders of atherosclerotic genesis
- anxiety disorders at neurotic and neurosis-like states
- an acute myocardial infarction (since the first day) as a part of complex therapy
- primary open angle glaucoma of various stages, as a part of complex therapy
- stopping of an abstinence syndrome in alcoholism with prevalence of neurosis-like and vegetovascular disorders
- acute intoxication antipsychotic means
- acute pyoinflammatory processes of an abdominal cavity (acute necrotic pancreatitis, peritonitis) as a part of complex therapy
the Route of administration and doses
Intramusculary or intravenously (struyno or by drop infusion). At an infusional method of administration of Meksidol® it is necessary to part in 0.9% chloride sodium solution. Meksidol® enter Struyno slowly within 5 - 7 min., by drop infusion — with a speed of 40 - 60 thaws a minute. The maximum daily dose should not exceed 1200 mg.
In acute disorders of cerebral circulation of Meksidol® apply in the first 10 - 14 days — intravenously by drop infusion 200 - 500 mg 2 - 4 times a day, then intramusculary on 200 - 250 mg 2 - 3 times a day within 2 weeks.
In a craniocereberal injury and consequences of craniocereberal injuries of Meksidol® apply within 10 - 15 days intravenously by drop infusion 200 - 500 mg 2 - 4 times a day.
In distsirkulyatorny encephalopathy in a phase of a decompensation Meksidol® it is necessary to appoint intravenously struyno or by drop infusion in a dose of 200 - 500 mg of 1 - 2 time a day for 14 days. Then intramusculary on 100 - 250 mg a day for the next 2 weeks.
For course prevention of distsirkulyatorny encephalopathy of Meksidol® 2 times a day for 10 - 14 days enter intramusculary in a dose 200 - 250 mg.
At easy cognitive disturbances at patients of advanced age and in anxiety disorders of Meksidol® apply intramusculary in a daily dose 100 - 300 mg a day for 14 - 30 days.
In an acute myocardial infarction as a part of complex therapy of Meksidol® enter intravenously or intramusculary within 14 days, against the background of the traditional therapy of a myocardial infarction including nitrates, beta blockers, inhibitors of angiotensin-converting enzyme (APF), a trombolitika, anticoagulating and antiagregantny means and also symptomatic means according to indications. For achievement of the maximum effect, Meksidol® it is desirable to enter the first 5 days intravenously, the next 9 days Meksidol® can be entered intramusculary. Intravenous administration of Meksidola® is made by drop infusion, slowly (in order to avoid side effects) for 0.9% solution of sodium of chloride or 5% solution of a dextrose (glucose) of 100 - 150 ml within 30 - 90 min. If necessary perhaps slow jet introduction of Meksidola®, lasting not less than 5 minutes.
Introduction of Meksidol® (intravenous or intramuscular) is carried out by 3 times a day, every 8 hours. The daily therapeutic dose makes 6 - 9 mg on body weight kg a day, a single dose — 2 - 3 mg on body weight kg. The maximum daily dose should not exceed 800 mg, single — 250 mg.
In an open angle glaucoma of various stages as a part of complex therapy of Meksidol® enter intramusculary 100 - 300 mg a day, 1 - 3 time a day within 14 days.
In an abstinence alcoholic syndrome of Meksidol® enter in a dose 200 - 500 mg intravenously by drop infusion or intramusculary 2 - 3 times a day within 5 - 7 days.
In acute intoxication antipsychotic means of Meksidol® enter intravenously in a dose 200 - 500 mg a day for 7 - 14 days.
At acute pyoinflammatory processes of an abdominal cavity (acute necrotic pancreatitis, peritonitis) Meksidol® appoint in the first day both in preoperative, and in the postoperative period. The entered doses depend on a form and disease severity, prevalence of process, options of a clinical course. Cancellation of Meksidola® has to be made gradually only after steady positive clinical laboratory effect.
In acute edematous (interstitial) pancreatitis of Meksidol® appoint 200 - 500 mg 3 times a day, intravenously by drop infusion (in 0.9% chloride sodium solution) and intramusculary.
Light severity of necrotic pancreatitis — on 100 - 200 mg 3 times a day intravenously by drop infusion (in 0.9% chloride sodium solution) and intramusculary. Moderate severity — on 200 mg 3 times a day, intravenously by drop infusion (in 0.9% chloride sodium solution). A heavy course — in pulse dosage of 800 mg in the first day, at the double mode of introduction, further on 200 - 500 mg 2 times a day with gradual decrease in a daily dose.
Extremely heavy course — in an initial dosage of 800 mg a day before permanent stopping of manifestations of pankreatogenny shock, on stabilization of a state on 300 - 500 mg 2 times a day intravenously by drop infusion (in 0.9% chloride sodium solution) with gradual decrease in a daily dosage.
Side effects
- nausea and dryness in a mouth, metal smack in a mouth
- drowsiness
- allergic reactions
- an unpleasant smell, irritation in a throat and discomfort in a thorax.
Contraindications
- the increased individual sensitivity to drug
- acute disorders of function of a liver and kidneys
- children's and teenage age up to 18 years
- pregnancy, the lactation period
Medicinal interactions
Strengthens effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), protivoparkinsonichesky means (levodopa), nitrates. Reduces toxic effects of alcohol.
Special instructions
In some cases, especially at predisposed patients with bronchial asthma at hypersensitivity to sulfites, development of heavy reactions of hypersensitivity is possible.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Should be careful at control of motor transport and potentially dangerous mechanisms.
Overdose
Symptoms: strengthening of side effects.
Treatment: drug is temporarily cancelled. Symptomatic treatment.
A form of release and packing
Solution of 50 mg/ml in ampoules on 2 ml or 5 ml, colourless or light-protective glass with a point of a break of blue color or with a point of a break of white color and three marking rings (upper - yellow, average - white, lower - red). On 5 ampoules in blister strip packaging from a film aluminum foil, polyvinylchloride without covering. On 1 (for ampoules on 5 ml) or 2 (for ampoules on 2 ml) blister strip packagings together with the instruction for medical use in the state and Russian languages put in a pack from cardboard.
To Store storage conditions in the dry, protected from light place, at a temperature not over 25 ºС.
To store out of children's reach!
3 years
not to apply a period of storage after the term specified on packing.
Prescription status
According to the prescription
LLC Ellara Adres Producer: Russia, 601122, Vladimir Region, Petushinsky district. A cover, Franz Stolwerk St., 20
the Owner of the registration certificate
of LLC NPK PHARMASOFT,
Russia Russia, 115280, Moscow, Avtozavodskaya St., 22
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Russia, 115280, Moscow, Avtozavodskaya St., 22
Ph./fax: +7 (495) 626-47-48
E-mail:
To Develop pharmasoft@pharmasoft.ru
of MEKSIDOL® medicine
the Trade name
of Meksidol®
the International unlicensed name
Is not present
the Dosage form
Solution for intravenous and intramuscular administration of 50 mg/ml on 2 ml or 5 ml
Structure
of 1 ml of solution contains
active agent - ethylmethylhydroxypyridine succinate - 50 mg,
excipients: sodium metabisulphite, water for injections
the Description
Transparent colourless or slightly yellowish liquid
Pharmacotherapeutic group
Drugs for treatment of diseases of nervous system others.
The ATX N07XX code
the Pharmacological
Pharmacokinetics At properties intramuscular introduction drug is defined in blood plasma for 4 hours after introduction. Time of achievement of the maximum concentration is 0.45 - 0.50 hours. The maximum concentration at doses of 400 - 500 mg makes 3.5 - 4.0 mkg/ml. Мексидол® quickly passes from the blood course into bodies and fabrics and it eliminirutsya quickly from an organism. Time of deduction (MRT) of drug in an organism is 0.7 - 1.3 hours. Drug is removed from an organism with urine generally in a glyukuronokonjyugirovanny form and in insignificant quantities in an invariable look.
The pharmacodynamics
Renders anti-hypoxemic, membranoprotektorny, nootropic, anticonvulsant, anxiolytic action, increases resistance of an organism to a stress. Мексидол® increases resistance of an organism to influence of the major disturbing factors, to kislorodzavisimy morbid conditions (shock, a hypoxia and ischemia, disturbance of cerebral circulation, intoxication alcohol and antipsychotic drugs (neuroleptics)).
Мексидол® improves brain metabolism and blood supply of a brain, improves microcirculation and rheological properties of blood, reduces aggregation of thrombocytes. Stabilizes membrane structures of blood cells (erythrocytes and thrombocytes) at hemolysis. Has hypolipidemic effect, reduces the level of the general cholesterol and lipoproteids of the low density (LDL).
Reduces an enzymatic toxaemia and endogenous intoxication in acute pancreatitis.
The mechanism of action Meksidola® is caused by its antigipoksantny, antioxidant and membranoprotektorny action. It inhibits processes of peroxide oxidation of lipids, increases activity of a superoxide scavenger, the lipid protein raises a ratio, reduces viscosity of a membrane, increases its fluidity. Modulates activity of membrane-bound enzymes (kaltsiynezavisimy phosphodiesterase, adenylatecyclase, acetylcholinesterase), receptor complexes (benzodiazepine, piperidic acid (GAMK), atsetilkholinovy) that enhances their ability of linking with ligands, helps preservation of the structurally functional organization of biomembranes, transport of neurotransmitters and improvement of synoptic transfer. Мексидол® increases dopamine content in a brain. Causes strengthening of compensatory activity of aerobic glycolysis and decrease in extent of oppression of oxidizing processes in a tricarbonic acid cycle in the conditions of a hypoxia, with increase in content of adenosine triphosphate (ATP), creatine phosphate and activation of the power synthesizing functions of mitochondrions, stabilization of cellular membranes.
Мексидол® normalizes metabolic processes in an ischemic myocardium, reduces a necrosis zone, restores and improves electric activity and contractility of a myocardium and also increases a coronary blood stream in an ischemia zone, reduces consequences of a reperfusion syndrome at acute coronary insufficiency. Increases anti-anginal activity of nitrodrugs. Мексидол® promotes preservation of ganglionic cells of a retina and fibers of an optic nerve at the progressing neuropathy which reasons chronic ischemia and a hypoxia are. Improves functional activity of a retina and optic nerve, increasing visual acuity.
Indications
- acute disorders of cerebral circulation
- a craniocereberal injury, consequences of craniocereberal injuries
- distsirkulyatorny encephalopathy
- vegeto-vascular dystonia
- slight cognitive disorders of atherosclerotic genesis
- anxiety disorders at neurotic and neurosis-like states
- an acute myocardial infarction (since the first day) as a part of complex therapy
- primary open angle glaucoma of various stages, as a part of complex therapy
- stopping of an abstinence syndrome in alcoholism with prevalence of neurosis-like and vegetovascular disorders
- acute intoxication antipsychotic means
- acute pyoinflammatory processes of an abdominal cavity (acute necrotic pancreatitis, peritonitis) as a part of complex therapy
the Route of administration and doses
Intramusculary or intravenously (struyno or by drop infusion). At an infusional method of administration of Meksidol® it is necessary to part in 0.9% chloride sodium solution. Meksidol® enter Struyno slowly within 5 - 7 min., by drop infusion — with a speed of 40 - 60 thaws a minute. The maximum daily dose should not exceed 1200 mg.
In acute disorders of cerebral circulation of Meksidol® apply in the first 10 - 14 days — intravenously by drop infusion 200 - 500 mg 2 - 4 times a day, then intramusculary on 200 - 250 mg 2 - 3 times a day within 2 weeks.
In a craniocereberal injury and consequences of craniocereberal injuries of Meksidol® apply within 10 - 15 days intravenously by drop infusion 200 - 500 mg 2 - 4 times a day.
In distsirkulyatorny encephalopathy in a phase of a decompensation Meksidol® it is necessary to appoint intravenously struyno or by drop infusion in a dose of 200 - 500 mg of 1 - 2 time a day for 14 days. Then intramusculary on 100 - 250 mg a day for the next 2 weeks.
For course prevention of distsirkulyatorny encephalopathy of Meksidol® 2 times a day for 10 - 14 days enter intramusculary in a dose 200 - 250 mg.
At easy cognitive disturbances at patients of advanced age and in anxiety disorders of Meksidol® apply intramusculary in a daily dose 100 - 300 mg a day for 14 - 30 days.
In an acute myocardial infarction as a part of complex therapy of Meksidol® enter intravenously or intramusculary within 14 days, against the background of the traditional therapy of a myocardial infarction including nitrates, beta blockers, inhibitors of angiotensin-converting enzyme (APF), a trombolitika, anticoagulating and antiagregantny means and also symptomatic means according to indications. For achievement of the maximum effect, Meksidol® it is desirable to enter the first 5 days intravenously, the next 9 days Meksidol® can be entered intramusculary. Intravenous administration of Meksidola® is made by drop infusion, slowly (in order to avoid side effects) for 0.9% solution of sodium of chloride or 5% solution of a dextrose (glucose) of 100 - 150 ml within 30 - 90 min. If necessary perhaps slow jet introduction of Meksidola®, lasting not less than 5 minutes.
Introduction of Meksidol® (intravenous or intramuscular) is carried out by 3 times a day, every 8 hours. The daily therapeutic dose makes 6 - 9 mg on body weight kg a day, a single dose — 2 - 3 mg on body weight kg. The maximum daily dose should not exceed 800 mg, single — 250 mg.
In an open angle glaucoma of various stages as a part of complex therapy of Meksidol® enter intramusculary 100 - 300 mg a day, 1 - 3 time a day within 14 days.
In an abstinence alcoholic syndrome of Meksidol® enter in a dose 200 - 500 mg intravenously by drop infusion or intramusculary 2 - 3 times a day within 5 - 7 days.
In acute intoxication antipsychotic means of Meksidol® enter intravenously in a dose 200 - 500 mg a day for 7 - 14 days.
At acute pyoinflammatory processes of an abdominal cavity (acute necrotic pancreatitis, peritonitis) Meksidol® appoint in the first day both in preoperative, and in the postoperative period. The entered doses depend on a form and disease severity, prevalence of process, options of a clinical course. Cancellation of Meksidola® has to be made gradually only after steady positive clinical laboratory effect.
In acute edematous (interstitial) pancreatitis of Meksidol® appoint 200 - 500 mg 3 times a day, intravenously by drop infusion (in 0.9% chloride sodium solution) and intramusculary.
Light severity of necrotic pancreatitis — on 100 - 200 mg 3 times a day intravenously by drop infusion (in 0.9% chloride sodium solution) and intramusculary. Moderate severity — on 200 mg 3 times a day, intravenously by drop infusion (in 0.9% chloride sodium solution). A heavy course — in pulse dosage of 800 mg in the first day, at the double mode of introduction, further on 200 - 500 mg 2 times a day with gradual decrease in a daily dose.
Extremely heavy course — in an initial dosage of 800 mg a day before permanent stopping of manifestations of pankreatogenny shock, on stabilization of a state on 300 - 500 mg 2 times a day intravenously by drop infusion (in 0.9% chloride sodium solution) with gradual decrease in a daily dosage.
Side effects
- nausea and dryness in a mouth, metal smack in a mouth
- drowsiness
- allergic reactions
- an unpleasant smell, irritation in a throat and discomfort in a thorax.
Contraindications
- the increased individual sensitivity to drug
- acute disorders of function of a liver and kidneys
- children's and teenage age up to 18 years
- pregnancy, the lactation period
Medicinal interactions
Strengthens effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), protivoparkinsonichesky means (levodopa), nitrates. Reduces toxic effects of alcohol.
Special instructions
In some cases, especially at predisposed patients with bronchial asthma at hypersensitivity to sulfites, development of heavy reactions of hypersensitivity is possible.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Should be careful at control of motor transport and potentially dangerous mechanisms.
Overdose
Symptoms: strengthening of side effects.
Treatment: drug is temporarily cancelled. Symptomatic treatment.
A form of release and packing
Solution of 50 mg/ml in ampoules on 2 ml or 5 ml, colourless or light-protective glass with a point of a break of blue color or with a point of a break of white color and three marking rings (upper - yellow, average - white, lower - red). On 5 ampoules in blister strip packaging from a film aluminum foil, polyvinylchloride without covering. On 1 (for ampoules on 5 ml) or 2 (for ampoules on 2 ml) blister strip packagings together with the instruction for medical use in the state and Russian languages put in a pack from cardboard.
To Store storage conditions in the dry, protected from light place, at a temperature not over 25 ºС.
To store out of children's reach!
3 years
not to apply a period of storage after the term specified on packing.
Prescription status
According to the prescription
LLC Ellara Adres Producer: Russia, 601122, Vladimir Region, Petushinsky district. A cover, Franz Stolwerk St., 20
the Owner of the registration certificate
of LLC NPK PHARMASOFT,
Russia Russia, 115280, Moscow, Avtozavodskaya St., 22
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Russia, 115280, Moscow, Avtozavodskaya St., 22
Ph./fax: +7 (495) 626-47-48
E-mail:
To Develop pharmasoft@pharmasoft.ru
Related Products
-19%
